Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Feb 19;330(7488):385.
doi: 10.1136/bmj.330.7488.385.

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

David Gunnell  1 , Julia Saperia, Deborah Ashby
Affiliations
Meta-Analysis

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

David Gunnell et al. BMJ. .

Erratum in

  • BMJ. 2006 Jul 1;333(7557):30

Abstract

Objective: To investigate whether selective serotonin reuptake inhibitor (SSRI) antidepressants are associated with an increased risk of suicide related outcomes in adults.

Design: Meta-analysis of randomised controlled trials of SSRIs compared with placebo in adults submitted by pharmaceutical companies to the safety review of the Medicines and Healthcare products Regulatory Agency (MHRA).

Participants: Over 40,000 individuals participating in 477 randomised controlled trials.

Main outcome measures: Suicide, non-fatal self harm, and suicidal thoughts.

Results: An estimated 16 suicides, 172 episodes of non-fatal self harm, and 177 episodes of suicidal thoughts were reported. We found no evidence that SSRIs increased the risk of suicide, but important protective or hazardous effects cannot be excluded (odds ratio 0.85, 95% credible interval 0.20 to 3.40). We found weak evidence of an increased risk of self harm (1.57, 0.99 to 2.55). Risk estimates for suicidal thoughts were compatible with a modest protective or adverse effect (0.77, 0.37 to 1.55). The relative frequency of reported self harm and suicidal thoughts in the trials compared with suicide indicates non-fatal end points were under-recorded.

Conclusion: Increased risks of suicide and self harm caused by SSRIs cannot be ruled out, but larger trials with longer follow up are required to assess the balance of risks and benefits fully. Any such risks should be balanced against the effectiveness of SSRIs in treating depression. When prescribing SSRIs, clinicians should warn patients of the possible risk of suicidal behaviour and monitor patients closely in the early stages of treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Forest plots of suicide, non-fatal self harm, and suicidal thoughts in placebo controlled trials of SSRIs
See this image and copyright information in PMC

Comment in

References

    1. Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H, and Office for National Statistics. Psychiatric morbidity among adults living in private households, 2000. London: Stationery Office, 2001. - PubMed
    1. Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm? BMJ 2004;329: 34-8. - PMC - PubMed
    1. Healy D, Langmaak C, Savage M. Suicide in the course of the treatment of depression. J Psychopharmacol 1999;13: 94-9. - PubMed
    1. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosomat 2003;72: 71-9. - PubMed
    1. Nutt D. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 2003;17: 355-64. - PubMed

Publication types

MeSH terms

Substances